Shasqi Boosts Leadership with Appointment of Former Pfizer Executive

Shasqi Strengthens Board of Directors

In a significant development, Shasqi, Inc., a pioneering biotech firm, has announced the appointment of Dr. Roger Dansey to its Board of Directors. With a wealth of experience from his previous leadership roles at Pfizer Oncology and Seagen, Dr. Dansey brings invaluable expertise in the domain of oncology and advanced cancer therapies.

Dr. Dansey's remarkable career encompasses over two decades at the forefront of drug development, notably including his tenure as Chief Development Officer at Pfizer, where he played a critical role in launching several groundbreaking cancer medications. His notable contributions include the development and commercialization of monoclonal antibodies and antibody-drug conjugates, which have transformed the landscape of cancer treatment.

Shasqi specializes in enhancing the effectiveness of cancer therapies through a novel approach called pre-targeting, which leverages the principles of click chemistry. This innovation was recognized globally with a Nobel Prize in 2022, underscoring its potential to revolutionize drug delivery systems. By enabling drugs to target tumors more effectively while minimizing exposure to healthy tissues, Shasqi aims to improve patient outcomes significantly.

According to Shasqi's Founder and CEO, Dr. José M. Mejía Oneto, the addition of Dr. Dansey is timely and strategic. "Roger's unique insights into the development of ADCs can expedite our mission to bring our lead drug candidate into clinical trial and expand our portfolio of pre-targeted cancer treatments," he stated.

Expressing his enthusiasm for joining the Shasqi team, Dr. Dansey remarked, "I'm delighted to be part of an organization that is poised to redefine cancer treatment paradigms. Shasqi's pre-targeting technology presents a promising frontier, enabling targeted delivery of therapies directly to tumors while reducing adverse effects."

About Shasqi

Shasqi, founded in 2014, focuses on applying cutting-edge advancements in click chemistry to the preclinical development of cancer therapeutics. The company's innovative Click Activated Protodrugs Against Cancer (CAPAC®) methodology is designed to boost drug efficacy while minimizing the side effects commonly associated with conventional treatments. Their approach utilizes a two-component system: a clickable binder and a clickable payload, designed to activate at the site of tumors, thereby enhancing the therapeutic window.

Shasqi has established itself as a leader in the field of translational click chemistry, being among the first to apply this technology to human treatments. As they embark on the next phase of their research initiatives and product development, the company aims to solidify its position as a frontrunner in the oncology biopharmaceutical landscape.

Conclusion

With the appointment of Dr. Roger Dansey, Shasqi is set to enhance its strategic vision for the future of cancer therapy. The combination of his experience with Shasqi's innovative technologies positions the company well to make meaningful advancements in oncology, offering hope to patients confronted with challenging cancer diagnoses. For those interested in following Shasqi's progress or exploring partnership opportunities, more information can be found at www.shasqi.com.